Herukka, SK;
Simonsen, AH;
Andreasen, N;
Baldeiras, I;
Bjerke, M;
Blennow, K;
Engelborghs, S;
... Waldemar, G; + view all
(2017)
Recommendations for CSF AD biomarkers in the diagnostic evaluation of MCI.
Alzheimer's and Dementia
, 13
(3)
pp. 285-295.
10.1016/j.jalz.2016.09.009.
Preview |
Text
Zetterberg_1-s2.0-S1552526016329648-main.pdf - Published Version Download (872kB) | Preview |
Abstract
This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.
| Type: | Article |
|---|---|
| Title: | Recommendations for CSF AD biomarkers in the diagnostic evaluation of MCI |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.jalz.2016.09.009 |
| Publisher version: | http://dx.doi.org/10.1016/j.jalz.2016.09.009 |
| Language: | English |
| Additional information: | Copyright © 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Keywords: | Alzheimer's disease; Biomarkers; CSF; Diagnostics; GRADE; Mild cognitive impairment; Recommendations |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/1537858 |
Archive Staff Only
 |
View Item |
